The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz Pharmaceuticals

 The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz
                               Pharmaceuticals

PR Newswire

CHICAGO, May 23, 2013

CHICAGO, May 23, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Zumiez Inc. (Nasdaq:ZUMZ), Mylan
Inc. (Nasdaq:MYL), AbbVie Inc. (NYSE:ABBV), Santarus, Inc. (Nasdaq:SNTS) and
Jazz Pharmaceuticals (Nasdaq:JAZZ).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday's Analyst Blog:

Zumiez Expected to Beat Earnings Ests

We expect Zumiez Inc. (Nasdaq:ZUMZ), a Wash.-based retailer of sports-related
teen apparel, to beat expectations when it reports first-quarter fiscal 2013
results on May 23.

Why a Likely Positive Surprise?

Our proven model shows that Zumiez may beat earnings because it has the right
combination of 2 key components.

Positive Zacks ESP: Zumiez currently has Earnings ESP (Read: Zacks Earnings
ESP: A Better Method) of +8.33%. This is because the Most Accurate Estimate
stands at 13 cents per share, while the Zacks Consensus Estimate is pegged at
12 cents.

Zacks #2 Rank (Buy): Note that stocks with a Zacks Rank #1, 2 and 3 have
higher chances of beating earnings. The Sell rated stocks (#4 and 5) should
never be considered going into an earnings announcement.

The combination of Zumiez's Zacks Rank #2 (Buy) and Earnings ESP of +8.33%
makes us confident of a positive earnings beat on May 23.

What's Driving the Better-than-Expected Earnings?

Zumiez's strategy relies on offering action-sports merchandise focused on
young men and women in the age of group of 12–24, which has enabled the
company to carve a distinct niche for itself. Furthermore, the company's
stores are strategically located in busy areas of the mall, such as food
courts, movie theatres and music/game stores, which are frequently visited by
its target customers. We also believe that Zumiez's initiatives such as store
opening programs and the acquisition of Blue Tomato has provided it a solid
platform to capitalize on the emerging opportunities.

The company has surpassed the Zacks Consensus Estimate in the trailing 4
quarters with an average surprise of approximately 19.6%.

Generic Launches at Mylan Continue

Mylan Inc. (Nasdaq:MYL) recently announced the launch of its generic version
of AbbVie Inc.'s (NYSE:ABBV) cholesterol management drug, TriCor (fenofibrate,
48 mg and 145 mg tablets). Mylan launched the drug after receiving final
approval from the US Food and Drug Administration regarding the Abbreviated
New Drug Application (ANDA) for its generic version of the drug.

We remind investors that Mylan is not the first to enter the US market with
its generic version of TriCor. In Nov 2012, Lupin Ltd. had launched its
generic version of TriCor. According to IMS Health, TriCor (48 mg and 145 mg)
generated US revenues of approximately $1.2 billion for the 12 months ending
Mar 31, 2013.

Mylan has a strong generic product portfolio and pipeline. As of May 17, 2013,
Mylan had 178 ANDAs pending FDA clearance, targeting $83.1 billion in sales
annually. Mylan believes that about 34 of these pending ANDAs are
first-to-file opportunities, representing $22.4 billion in branded sales. The
revenue figures are as per IMS Health for the 12 months ending June 30, 2012.

Mylan carries a Zacks Rank #3 (Hold). Mylan's geographic reach and product
depth, along with a robust generic pipeline, are contributing to its overall
growth.

However, we remain cautious of the company's lackluster performance in Europe,
the Middle East and Africa. Additionally, as most of the large branded drugs
are due to lose patent exclusivity within the 2017–2018 period, we have little
visibility on the growth prospects of generic companies like Mylan beyond that
timeframe.

Currently, companies like Santarus, Inc. (Nasdaq:SNTS) and Jazz
Pharmaceuticals (Nasdaq:JAZZ) look attractive with both being Zacks Rank #1
(Strong Buy) stocks.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.